Optimizing therapy and management of neurogenic bladder.
Clinicians managing patients with neurogenic bladder (NGB) and neurogenic detrusor overactivity (NDO) are faced with a myriad of complex choices when deciding on appropriate medical and/or surgical interventions to relieve bothersome symptoms associated with NGB and NDO, especially urinary incontinence. Therapies must provide maximum benefits while minimizing patients' risk for adverse events. A thorough knowledge and understanding of available and emerging medical and surgical treatment options for NGB/NDO is vital to assist clinicians in choosing appropriate treatment pathways and optimize response to therapy and individual outcomes.
Ginsberg@med.usc.edu.
David
D
Ginsberg
D001676:Biofeedback, Psychology; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D004327:Drinking Behavior; D004599:Electric Stimulation Therapy; D006801:Humans; D008019:Life Style; D018727:Muscarinic Antagonists / Q000627:therapeutic use; D009465:Neuromuscular Agents / Q000627:therapeutic use; D012648:Self Care; D001750:Urinary Bladder, Neurogenic / Q000628:therapy*; D014546:Urinary Catheterization; D013520:Urologic Surgical Procedures
D018727:Muscarinic Antagonists; D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A